TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02518607

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MGB-BP-3
Description: Treatment of CDI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MGB-BP-3
Description: Treatment of CDI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MGB-BP-3
Description: Treatment of CDI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MGB-BP-3
Description: Treatment of CDI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MGB-BP-3
Description: Treatment of CDI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MGB-BP-3
Description: Treatment of CDI

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03126422

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Pretreatment of different doses of dexmedetomidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Pretreatment of different doses of dexmedetomidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Pretreatment of different doses of dexmedetomidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Pretreatment of different doses of dexmedetomidine
Study: NCT02333474

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard treatment
Description: Patient will receive a comprehensive histological and imaging check up to evaluate the histological type, stage of the disease and performance status. Then the patient will receive standard treatment, in brief, surgical resection for early stage patients and systemic treatment including chemotherapy for advanced stage patients, according to NCCN guide line.
Study: NCT03320993

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mixed meal with different macronutrient composition
Description: A mixed meal with identical amount of carbohydrates but different content of protein, fat and alcohol will be given

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mixed meal with different macronutrient composition
Description: A mixed meal with identical amount of carbohydrates but different content of protein, fat and alcohol will be given

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mixed meal with different macronutrient composition
Description: A mixed meal with identical amount of carbohydrates but different content of protein, fat and alcohol will be given
Study: NCT03282994

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dermal Cooling System
Description: Cryotherapy
Study: NCT02168699

Intervention type: OTHER
Group type: OTHER
Intervention: Ultrasound examination of the axilla
Study: NCT01919671

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tongxinluo capsule
Description: for 90 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo capsule
Description: for 90 days
Study: NCT00879099

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paroxetine
Description: Paroxetine 20 mg once a day during two treatment periods. One treatment period lasts for 3 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Gelatine capsule once a day during two treatment periods. One treatment period lasts for 3 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: timolol maleate
Description: Oftan Timolol 0,5 % eye drop. One drop into both eyes on day 3 after taking paroxetine or placebo capsules for three days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: timolol maleate
Description: Timosan 0,1 % eye gel. One drop into both eyes on day 3 after taking paroxetine or placebo capsules for three days.
Study: NCT00662454

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ethinyl estradiol / levonorgestrel
Description: Take one tablet daily of 20 mcg ethinyl estradiol/100 mcg levonorgestrel for 21 days plus 7 days of placebo tablets, repeat for two months total duration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ethinyl estradiol / levonorgestrel
Description: Take one tablet daily of 20 mcg ethinyl estradiol/100 mcg levonorgestrel for 21 days plus 7 days of placebo tablets, repeat for two months total duration.
Study: NCT04269707

Intervention type: DRUG
Group type: OTHER
Intervention: Ferric carboxymaltose
Description: IV iron
Study: NCT01497275

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab, Bortezomib,Y90 ibritumomab tiuxetan
Description: Rituximab 250mg/m2 will be given on day 1 and on day 8. Bortezomib 1.5mg/m2 will be given on Days 1, 4, 8, and 11. Y90 ibritumomab tiuxetan will be given on Day 8. Dosage will be based on the platelet count obtained at the time of study enrollment. The dose will be 0.4mCi/kg unless the enrollee's platelets are between 100,000 and 150,000 in which case a dose of 0.3mCi/Kg will be used. Patients who weigh over 80 Kg will receive a maximum dose of 32mCi.
Study: NCT04069962

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CGA coordination by geriatric team including intensive patient coaching and follow-up
Description: In the intervention group, the CGA including geriatric recommendations for interventions will be coordinated by the geriatric team and will be complemented with patient coaching. This intervention aims to support patient empowerment by improving self-efficacy and supporting self-management of existing age-related problems before systemic therapy or occurring during systemic therapy, and includes an individual counselling session at start of systemic therapy to discuss the recommendations with the patient and to determine their priorities.
Study: NCT02617888

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: CCTA ~ BREAST SHIELDS
Description: Breast shield placement (randomized) among women.
Study: NCT02103712

Intervention type: OTHER
Intervention: Qualitative
Study: NCT01549600

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: psyllium
Description: 1 level tablespoon (\~ 5.1 g psyllium husk in the psyllium product) mixed with at least 8 ounces of water, taken twice daily

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Microcrystalline Cellulose
Description: 1 level tablespoon (\~ 1.18 g MCC in the MCC product) mixed with at least 8 ounces of water, taken twice a day
Study: NCT02357979

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser
Description: CO2 - 9.3μm short-pulsed laser irradiation will occur on the occlusal enamel surface. This results in changes in crystal composition and structure, which increase the resistance of dental mineral to dissolution by acid and will work to better prevent dental caries in the occlusal surface of vital teeth when compared to fluoride therapy alone over 12 months.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fluoride
Description: The Fluoride varnish is painted on the occlusal surface of the tooth. Fluoride varnish makes enamel more acid resistant.
Study: NCT01680887

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03973788

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: repetitive transcranial magnetic stimulation (rTMS)
Description: A single section of rTMS (2,000 pulses)
Study: NCT02569307

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Minocycline
Description: Minocycline added to TAU Minocycline will be administered in 200mg once daily dose
Study: NCT02694263

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Description: Comparison of Canagliflozin (Invokana™) vs. standard dual therapy (Repaglinide, Pioglitazone, Gliclazide or Glimepiride) for the treatment of Type 2 Diabetes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Repaglinide
Description: Comparison of Canagliflozin (Invokana™) vs. standard dual therapy (Repaglinide) for the treatment of Type 2 Diabetes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: Comparison of Canagliflozin (Invokana™) vs. standard dual therapy (Pioglitazone) for the treatment of Type 2 Diabetes.
Study: NCT02569307

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3 fatty acids
Description: Omega-3 fatty acids added to TAU Omega-3 fatty acids will be administered in 1.2g once daily dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo added to TAU

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Minocycline Plus Omega-3 fatty acids
Description: Minocycline will be administered in 200mg once daily dose and Omega-3 fatty acid 1.2g taken as once daily dose
Study: NCT00432627

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferasirox
Description: one dose of 20 mg/kg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferasirox
Description: one dose of 20 mg/kg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferasirox
Description: one dose of 20 mg/kg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferasirox
Description: one dose of 20 mg/kg/day
Study: NCT02631252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Doses ranging from 600-1400mg daily in divided twice daily doses and administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Description: Dose: 10mg/m2 IVPB in 50ml NS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Dose: 100 mg/m2 administered intravenously in 500 ml of 0.9% sodium chloride
Study: NCT04459130

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Child Obesity Program
Description: The program consists of 10 sessions, each lasting 40 minutes. An EOP booklet containing session programs will be distributed to children.~The topics of the sessions are as follows:~Session 1: Healthy lifestyles~* Session 2: Self-esteem and positive thinking, Setting goals Session 3: Stress and Coping, Coping with Emotions in Healthy Ways Session 4: Personality and effective communication~* Session 5: Activity: Time for action Session 6: Nutrition basics Session 7: Reading tags Session 8: Portion size, nutrition and healthy food choices in schools Session 9: Snacks can also be healthy: Healthy choices~* Session 10: Together for a healthy life (Melnyk et al., 2006; 2007; 2009). Detailed information about the sessions is given in annex -3.
Study: NCT03788356

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training
Description: Inspiratory muscle training with a device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training
Description: Inspiratory muscle training with a device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training
Description: Inspiratory muscle training with a device
Study: NCT02017106

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endovenous Laser ablation and sequential phlebectomies
Study: NCT03617510

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Felbinac Trometamol Injection
Description: Felbinac Trometamol Injection will be infused IV in 100 mL normal saline,in a 30-minute period using a programmable pump.Three days after the single dose,the drug was given 7 times,3 times/day,once every 8 hours. It means the drug was given 3 times on D3 and D4,once on D5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Felbinac Trometamol Injection
Description: Felbinac Trometamol Injection will be infused IV in 100 mL normal saline,in a 30-minute period using a programmable pump.Three days after the single dose,the drug was given 7 times,3 times/day,once every 8 hours. It means the drug was given 3 times on D3 and D4,once on D5.
Study: NCT02017106

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endovenous Laser ablation and sequential phlebectomies
Study: NCT02694263

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gliclazide
Description: Comparison of Canagliflozin (Invokana™) vs. standard dual therapy (Gliclazide) for the treatment of Type 2 Diabetes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride
Description: Comparison of Canagliflozin (Invokana™) vs. standard dual therapy (Glimepiride) for the treatment of Type 2 Diabetes.
Study: NCT03843073

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Connected Urinary Catheter
Description: Patients will use the Connected Catheter to empty the bladder during the course of treatment.
Study: NCT01586715

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adipose-derived stem cells without expanded
Description: Administration will be intralesional injection of cells suspension. They will be placed into fistula walls
Study: NCT01926509

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8892

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8892

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8892

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for MK-8892
Study: NCT04403685

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Single-dose infusion of 8 mg/kg. Maximum dose of 800 mg.
Study: NCT00663260

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin
Description: Tablets, Oral, 10 mg, Once Daily, 104 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin
Description: Tablets, Oral, 5 mg, Once Daily, 104 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets, Oral, 0 mg, Once Daily, 104 weeks
Study: NCT04160598

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV infusion
Description: Control group (Placebo Group): bolus 50 ml Nacl 0.9% at the end of surgery over 20 minutes 5ml/minute infusion rate.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IV infusion
Description: Control group (Placebo Group): bolus 50 ml Nacl 0.9% at the end of surgery over 20 minutes 5ml/minute infusion rate.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intrathecal fentanyl
Description: 10-15mg hyperbaric bupivacaine and 30µg fentanyl intrathecally injected

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: intrathecal fentanyl
Description: 10-15mg hyperbaric bupivacaine and 30µg fentanyl intrathecally injected
Study: NCT00745355

Intervention type: BEHAVIORAL
Intervention: Quality Of Life questionnaires
Description: All patients who agree to participate will be interviewed using a baseline idiographic quality of life assessment prior to surgery and at approximately 6, 12, 18 and 24 months postoperatively. All patients will also be asked to respond to a questionnaire including all standard measures (closed-ended, multiple choice items) before surgery and at approximately 3, 6, 12, 18 and 24 months post-surgery.
Study: NCT00803049

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriflunomide (HMR1726)
Description: Tablet, oral administration QD.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriflunomide (HMR1726)
Description: Tablet, oral administration QD.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriflunomide (HMR1726)
Description: Tablet, oral administration QD.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriflunomide (HMR1726)
Description: Tablet, oral administration QD.
Study: NCT01701609

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation Therapy
Study: NCT03842150

Intervention type: DIAGNOSTIC_TEST
Intervention: biliary atresia screen score
Description: The investigators aim to develop a scoring system according to clinical, laboratory, imaging features of biliary atresia in the derivation dataset and tested in the validation datasets.

Intervention type: DIAGNOSTIC_TEST
Intervention: biliary atresia screen score
Description: The investigators aim to develop a scoring system according to clinical, laboratory, imaging features of biliary atresia in the derivation dataset and tested in the validation datasets.
Study: NCT00660231

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bexarotene
Description: Bexarotene daily p.o. 150mg/sq m during week 1 and 2, then 300mg/sq m if tolerated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Gemcitabine i.v. 1000mg/sq m day 1 and day 8 of four 21 day cycles.
Study: NCT02624479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium thiosulfate
Description: oral administration of thiosulfate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium thiosulfate
Description: oral administration of thiosulfate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium thiosulfate
Description: oral administration of thiosulfate
Study: NCT01909245

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogenic Human Islet Cells
Description: Intraportal (into the liver) infusion of islet cells, with a maximum of three islet transplants.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immunosuppressive Agents
Description: Anti-rejection medications (to prevent the body from rejecting the islet cells) and other medications to guard against infection and support participant health and/or the health of the transplanted islets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gastrin 17
Description: Gastrin-17 (or GAST-17) - a gut hormone injected under the skin for 30 days (optional treatment for islet dysfunction).
Study: NCT03969030

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PEBRA model
Description: The participants in the intervention clusters are offered the PEBRA model. In the PEBRA model the ART visit/refill is coordinated by the PE, as much as feasible according to the participants' preferences. Thus, the preferences of each participant are captured at enrolment and after a strict schedule thereafter. The PE conducts the preference assessment using a tablet-based application, called PEBRApp, accoring to a specific schedule. First, the participant will be asked his/her preference regarding different domains of DSD (see below) and this will be entered into the PEBRApp. Secondly, the chosen preferences are assessed regarding feasibility with specific questions, as not all preference options are available to everyone all the time. The preference assessment entails the following three domains of DSD:~1. ART Refill~2. SMS notifications~3. Support
Study: NCT04103931

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment Choices for Aortic Stenosis Decision Aid
Description: A decision aid, titled Treatment Choices for Aortic Stenosis, produced by the American College of Cardiology that contains information for patients deciding between TAVR and surgery to treat their aortic stenosis.
Study: NCT03617510

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Felbinac Trometamol Injection
Description: Felbinac Trometamol Injection will be infused IV in 100 mL normal saline,in a 30-minute period using a programmable pump.Three days after the single dose,the drug was given 7 times,3 times/day,once every 8 hours. It means the drug was given 3 times on D3 and D4,once on D5.
Study: NCT01491919

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lisinopril
Description: Subjects will be randomized to Low, Medium, or High dose of Lisinopril

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lisinopril
Description: Subjects will be randomized to Low, Medium, or High dose of Lisinopril

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lisinopril
Description: Subjects will be randomized to Low, Medium, or High dose of Lisinopril
Study: NCT04637347

Intervention type: DEVICE
Group type: OTHER
Intervention: Catheterization approach
Description: In plane infraclavicular subclavian vein VS in plane supraclavicular subclavian vein catetherization

Intervention type: DEVICE
Group type: OTHER
Intervention: Catheterization approach
Description: In plane infraclavicular subclavian vein VS in plane supraclavicular subclavian vein catetherization
Study: NCT00522379

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rotigotine
Description: 2 mg/24 hr (one 10 cm\^2) transdermal patch applied daily for titration and maintenance period - 16 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rotigotine
Description: 4 mg/24 hr (one 20 cm\^2) transdermal patch applied daily for titration and maintenance period - 16 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo transdermal patch applied daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rotigotine
Description: 6 mg/24 hr (one 10 cm\^2 \& one 20 cm\^2) transdermal patches applied daily for titration and maintenance period - 16 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rotigotine
Description: 8 mg/24 hr (two 10 cm\^2 \& one 20 cm\^2) transdermal patches applied daily for titration and maintenance period - 16 weeks